Cornerstone Planning Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cornerstone Planning Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-97	Closed	-$25.9K	–	238
2026 Q2	$25.9K	Sell	97 -3	-3%	-$905	﹤0.01%	587
2026 Q1	$30.1K	Buy	100 +5	+5%	+$1.7K	﹤0.01%	542
2025 Q4	$33.2K	Sell	95 -397	-81%	-$176K	0.01%	443
2025 Q3	$56.2K	Buy	492 +450	+1,071%	+$183K	0.01%	314
2025 Q2	$17.6K	Buy	42 +8	+24%	+$2.21K	﹤0.01%	446
2025 Q1	$8.23K	Buy	34 +11	+48%	+$2.83K	﹤0.01%	620
2024 Q4	$6.36K	Hold	23	–	–	﹤0.01%	530
2024 Q3	$6.55K	Buy	23 +10	+77%	+$2.6K	﹤0.01%	511
2024 Q2	$3.44K	Buy	+13	New	+$2.05K	﹤0.01%	650
2024 Q1	–	Sell	-1	Closed	-$191	–	1109
2023 Q4	$191	Hold	1	–	–	﹤0.01%	865
2023 Q3	$177	Buy	+1	New	+$191	﹤0.01%	1040

Other funds holding ALNY

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Portman Square Capital London, United Kingdom $1.77B AUM 15.29% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return

Cornerstone Planning Group's ALNY Position: Q3 2026 in Review

Cornerstone Planning Group sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2026, closing a stake of 97 shares — an estimated $25.9K sold.

Cornerstone Planning Group first reported a position in ALNY in Q3 2023 and held it in 11 quarters. The position peaked at $56.2K in Q3 2025. 125 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Cornerstone Planning Group reported no remaining Alnylam Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Cornerstone Planning Group sold 97 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $25.9K.
Cornerstone Planning Group first reported a position in Alnylam Pharmaceuticals in Q3 2023 and held it in 11 quarters.
Cornerstone Planning Group's Alnylam Pharmaceuticals position peaked at $56.2K in Q3 2025.
125 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Cornerstone Planning Group's 13F filing for Q3 2026, filed 16 Oct 2026.